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Abstract
Introduction: T cell and NK cell cytotoxicity can be mediated via the perforin/
granzyme system and Fas Ligand (FasL, CD178). FasL is synthesized as a type II
transmembrane protein that binds its cognate receptor Fas (CD95). Membrane-
bound FasL is expressed on the plasma membrane of activated lymphocytes and is
the main form of FasL with cytotoxic activity, but whether FasL is delivered to the
immune synapse along with granzyme and perforin-containing granules is unclear.
Methods: We stably expressed FasL-fluorescent fusion proteins into human NK
cells and examined the localization of FasL relative to other intracellular markers by
confocal and immunoelectron microscopy, and examined the trafficking of FasL
during formation of immune synapses with HLA-deficient B cells.
Results: FasL co-localized with CD63 more strongly than perforin or Lamp1þ in
cytolytic granules. Electron microscopy revealed that FasL is enriched on
intraluminal vesicles (ILVs) adjacent to the dense-core within cytolytic granules.
In NK cells forming immune synapses with HLA-deficient B cells, a portion of
FasL-containing granules re-localize toward the immune synapse, while a distinct
pool of FasL remains at the distal pole of the cell.
Conclusions: Localization of FasL to intra-luminal vesicles within cytolytic
granules facilitates FasL trafficking to immune synapses and cytotoxic function in
NK cells.
Introduction
Natural killer (NK) and cytotoxic CD8þ T lymphocytes
(CTL) kill virus-infected and tumor cells through the
targeted delivery of cytotoxic granules. These cells can
induce target cell death though two major mechanisms. One
involves the rapid release of lytic granules containing
cytotoxic molecules including perforin and granzymes
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into a synaptic cleft formed between the effector and target
cell upon triggering of the TCR or NK cell activating
receptors. Upon perforin-facilitated entry into the target cell,
granzyme protease activity cleaves critical cellular substrates
leading to rapid DNA degradation and cell death. The
second mechanism involves interactions between the TNF-
family cytokine Fas ligand (FasL, CD178) on effector cells
with its cognate receptor Fas (CD95) on the cell surface of
target cells. The binding of membrane-bound FasL with Fas
induces cell death during target cell killing as well as
autocrine and paracrine T cell death [1]. Although the
perforin/granzyme system mediates efficient target cell
killing, both CTL and NK cells appear to use FasL to
some extent to kill target cells. In CTL, deficiencies in either
the perforin-mediated or Fas-FasL pathway impairs, but
does not completely abolish the killing ability of CTLs,
whereas deficiencies of both systems abolish CTL activity [2,
3]. In NK cells, cytolytic activity can also be significantly
inhibited in the presence of antibodies against Fas,
suggesting a non-redundant role for FasL-Fas interactions
in NK cell-mediated cytotoxicity as well [4, 5]. Thus, the
FasL-Fas pathway appears to be an alternate lytic system to
the perforin/granzyme pathway in both CTL and NK cells.
Genetic studies have revealed that Fas-FasL interactions are
important in maintaining lymphocyte homeostasis and
immunological self-tolerance, as seen in the lympho-
accumulation and autoantibody formation that ensues
from deficiency in either Fas or FasL in lpr and gld mice [6,
7]. In humans, dominant negative mutations in Fas or FasL
cause most cases of the Autoimmune Lymphoproliferative
Syndrome (ALPS) [8, 9]. FasL-Fas interactions also play a role
in killing virally infected cells andmaintaining homeostasis of
the anti-viral CTL pool during chronic infection [10–12].
These studies highlight the importance of understanding the
mechanism by which FasL kills target cells.
FasL is synthesized as a type II transmembrane protein
and can be secreted in soluble form after cleavage of the
extracellular Fas-binding domain by the metalloprotease
ADAM10 [13]. However, soluble FasL does not exert
cytotoxicity and may in some cases inhibit apoptosis
induced by membrane-bound FasL [14]. Membrane-bound
surface FasL increases significantly uponT cell activation [15,
16], and FasL at the plasma membrane may be capable of
exerting lytic functions that would not require conjugate
formation and directional granule release. Additionally, FasL
has been detected on the membranes of secreted micro-
vesicles, which are thought to derive from the inner vesicles
of multivesicular bodies (MVB). Vesicular FasL may also be
cytotoxic [17–20], but would require directed secretion into
the immunological synapse for efficient function. Which of
these forms of membrane FasL exerts cytotoxicity, and
whether FasL traffics to the immunological synapse upon
TCR and NK cell receptor triggering, is not known.
To better understand the mechanisms by which NK cells
use FasL to kill target cells, we studied the intracellular
localization of FasL in human NK cells virally transduced
with FasL-fluorescent fusion proteins. We found that FasL is
enriched on the membranes of intraluminal vesicles (ILVs)
within CD63 and LAMP1-expressing secretory lysosomes,
but is not found in the dense cores of secretory lysosomes,
where perforin is present. FasL-containing secretory lyso-
somes accumulated at the immune synapse during NK-cell
recognition of MHC-deficient target cells, with a secondary
pool of FasL vesicles accumulating at the pole opposite to the
immune synapse. These studies identify vesicular FasL as the
form of FasL that is delivered to the immune synapse,
mediating its cytotoxic potential.
Results
FasL local izes to a secretory lysosome
compartment distinct from perforin in human
NK cells
Previous studies in transiently transfected RBL cells and
native FasL in fixed T and NK cells have shown that FasL
primarily localizes in secretory lysosomes with a minority
of FasL on the cell surface [21]. To examine FasL
trafficking in living human NK cells, we generated clones
of the human NK cell line YT that were retrovirally
transduced to stably express a chimeric FasL protein with
GFP fused to its intracellular amino terminus. To prevent
spontaneous cytotoxic activity of FasL, the Fas-binding
sequence of the extracellular domain of FasL (amino acid
residue 218) was altered with a point mutation derived
from gld mice, rendering FasL non-functional [22–24]. YT
clones expressing FasL-GFP at equivalent levels were
selected for study.
We first examined FasL localization in YT cell clones
expressing FasL-GFP using confocal microscopy. Immuno-
stained FasL and GFP showed complete colocalization,
validating GFP as a marker for FasL (Fig. S1). Using
antibodies labeling CD63, LAMP1, and perforin-positive
compartments in NK cells, we studied the subcellular
localization of FasL relative to components of the secretory
lysosome. LAMP1 is a protein found on the limiting
membrane of lysosomes, while CD63 is a protein found both
on the limiting membrane and on the internal membranes of
MVBs. In contrast, perforin and granzymes are often found
in the dense core of secretory lysosomes [27–29]. We
observed the greatest overlap between FasL and CD63þ
compartments, with reduced colocalization with LAMP1 or
perforin (Fig. 1). Quantitative image analysis of colocaliza-
tion in multiple cells confirmed this hierarchy, with greater
colocalization of FasL with CD63 than with LAMP1 or
perforin (Fig. 2).
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In addition we analyzed cells using a ‘‘line-tool’’
method to visualize the degree of co-localization between
FasL and secretory compartments. This method quanti-
tates the peak overlaps that occur between FasL and
immunostained granules along a line selected to go
through multiple granules in a single optical slice of the
cell (Fig. S2). Concordant with the colocalization analysis
shown in Figure 2, there was more frequent overlap in the
peaks between FasL and CD63 than with perforin or
LAMP1, although FasL was frequently observed in close
proximity perforin, suggesting that they may in distinct
compartments within the secretory lysosome. Taken
together, these data show that in lymphocytes before
contact with a target cell, FasL is enriched in CD63þ
vesicles and adjacent, but not colocalized with perforin
within granules.
To investigate the localization of FasL in secretory
vesicles in relation to perforin and granzyme B in more
detail, we used immunogold labeling with an antibody
against GFP to localize the FasL-GFP fusion protein via
electron microscopy (EM). In YT cells stably expressing
FasL-GFP, the GFP signal was detected predominantly on
the ILVs within the secretory lysosomes, but was excluded
from the electron dense cores which contain perforin and
granzymes (Fig. 3A,B). The number of gold particles per
intraluminal vesicle (ILV) carrying FasL, ranged from 1 to
12 gold particles per ILV (mean¼ 3, n¼ 66) (Fig. 3B). In
addition, we detected minor gold labeling FasL-GFP in the
Figure 1. FasL in NK cells predominantly colocalizes to CD63þ vesicles distinct from LAMP1 and perforin. Confocal immunoﬂuorescence microscopy
(mid-cell slices) of YT cells stably expressing FasL-GFP (green)were stainedwith anti-LAMP1 antibody to label LAMP1þ compartments (red) (A), anti-CD63
antibody to label CD63þ compartments (red) (B), and with anti-perforin antibody (dG9) to label perforin-containing compartments (red) (C). The nuclei
of YT cells were labeled with Hoechst dye (blue).
FasL localization in the NK cell immune synapse J. Lee et al.
314 © 2018 The Authors. Immunity, Inflammation and Disease Published by John Wiley & Sons Ltd.
Golgi (Fig. 3C). These data show that FasL is sorted to the
ILVs of secretory lysosomes, positioning FasL to be present
on the surface of a secreted vesicle in membrane-bound
form, whereas FasL was not present in the electron-dense
cytolytic granules
FasL relocalizes toward the immune synapse upon
target cell recognition
To examine the trafficking behavior of FasL during
interactions between NK and target cells, we imaged FasL-
GFP in YT cells that had formed conjugates with 721.221
cells, a human B cell line lackingMHC class I expression. The
lack of MHC class I relieves signaling through inhibitory
receptors on NK cells, enabling conjugate formation, NK cell
activation and target cell killing. We identified YT cells that
had formed immune synapses with target cells as those in
which perforin re-localized to the interface with the target
cell. Confocal images of YT cells in which endogenous
perforin had re-localized to the site of contact with 721.221 B
cells revealed three distinct patterns of FasL-GFP localization
(Fig. 4C). In 52% of conjugates analyzed (n¼ 42),
intracellular FasL-containing vesicles polarized toward the
immunological synapse and colocalized with perforin, with
some FasL remaining at the distal pole of the cell (Fig. 4A). In
other conjugates (26%), almost all FasL was proximal to the
immunological synapse (Fig. 4B). FasL was exclusively
localized to the distal pole of the cell only in 5% of conjugates
examined. These results suggest that FasL is delivered to the
immunological synapse after target cell recognition, but less
efficiently than perforin, with a significant percentage of cells
retaining FasL-containing vesicles at the opposite pole of the
cell, distal from the immune synapse.
To confirm FasL localization to the IS in with other
markers of the immune synapse in living cells, we
imaged NK-cells transduced with FasL-GFP forming
conjugates with 721.221 B cells using live cell confocal
video microscopy. FasL could be seen to localize to the
immune synapse in the central area of the IS surrounded
by F-actin labeled by transfected LifeAct-EGFP
(Fig. 5A). The accompanying video (supplemental video
1) shows that FasL relocalizing away from the IS with
similar kinetics to disassembly of F-actin at the target
cell interface. Imaging of FasL with CD63-mCherry
revealed colocalization of FasL and CD63 in the central
portion of the NK-B immune synapse (Fig. S3, supple-
mental video 2).
We asked whether FasL is released in vesicles upon
degranulation by treating YT cells expressing FasL-GFP with
PMA and ionomycin before fixation and labeling. Electron
micrographs showed that small vesicles released upon
degranulation were labeled with FasL-GFP, demonstrating
Figure 2. Quantitation of FasL colocalization with vesicle markers. The
Pearson coefﬁcient of FasL colocalization with LAMP1, perforin, CD63,
and GFP is shown, with each point representing colocalization within an
image stack. Asterisks indicate statistically signiﬁcant colocalization
differences for FasL with the indicated marker via Mann-Whitney test
(two-tailed, 95% conﬁdence intervals), with CD63 vs LAMP1: p¼ 0.025
(); GFP-FasL to CD63 vs GFP-FasL to anti-GFP: p< 0.0001(); and
LAMP1 versus Perforin: nonsigniﬁcant, p¼ 0.817 (n.s).
Figure 3. Ultrastructural analysis of FasL localization in YT cells.
Representative electron microscopy images of immunogold-labeled
cryo-sections from stable YT cells expressing GFP-tagged FasL, visualized
with anti-GFP and protein-A gold particles. (A) Shows the electron dense
core and intraluminal vesicles of cytolytic granules bound by an outer
limiting membrane, with FasL gold particle labeling exclusively in the
intraluminal vesicles and not the dense core. (B) shows an MVB that
contains only ILVs with prominent immunogold labeling. In (C) GFP-FasL
labeling is shown within the Golgi stack. Scale bars¼ 200 nm.
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Figure 4. Distinct patterns of FasL subcellular localization during immune synapse formation. (A) and (B) Confocal immunoﬂuorescence microscopy of
YT cells stably expressing FasL-GFP (green) in conjugates with target HLA class I-deﬁcient 721.221 B cells were labeled with anti-perforin (dG9) to mark
perforin granules (red). Examples of FasL localized to the synapse and distal pole (A) and synapse exclusively (B) are shown. The nuclei of target B cells
were pre-labeled with Coumarin-blue dye. All images were taken 0–12min after YT cells came into contact with 721.221 B cells. (C) Quantiﬁcation
(percentages) of YT:B cell conjugates (n¼ 42) that displayed FasL localization at the distal pole, immune synapse, or both.
FasL localization in the NK cell immune synapse J. Lee et al.
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that FasL is released in a membrane bound form upon
secretion (Fig. 5C).
Discussion
The transport and release of lytic proteins at the
immunological synapse during target cell killing depends
on the successful sorting of these proteins to secretory
compartments. Human NK cells store lytic proteins such as
perforin and granzymes in secretory lysosomes until signaled
for degranulation [25]. Our results identify CD63þ intra-
luminal vesicles (ILVs) within MVB as the primary
subcellular compartment where FasL is localized. These
results extend our earlier findings that FasL partially
colocalized with perforin, cathepsin D, and granzyme A in
NK cells [2]. We now show that FasL is primarily localized to
Figure 5. FasL localization to the immune synapse visualized during cell conjugate formation. (A) Still image from supplemental Video File 1, showing
confocal immunoﬂuorescence microscopy images of live YT cells stably expressing FasL-GFP (green) transfected with a LifeAct-mApple to label F-actin
(red). The image shows the time of maximal actin polymerization, which corresponds to FasL accumulation in the center of the immune synapse. (B) 3D
projection and an image slice through the center of an NK:B cell conjugate showing the localization of FasL-GFP (green) relative to Life-Act (Red) and
target cell nuclei (blue) (C) Immuno-gold labeling of FasL in YT cells expressing FasL-GFP treated with PMA and Ionomycin to induce degranulation. IC,
Intracellular space; EC, Extracellular space, arrowheads mark FasL labeling.
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a broader population of CD63þ vesicles, with a smaller
fraction of FasL colocalizing with LAMP1þand perforinþ
mature secretory granules. The EM immunostaining
revealed that FasL is localized to the ILVs of cytolytic
granules, and is excluded from mature dense-core vesicles
where perforin and granzymes are localized [26–29],
concordant with the confocal microscopy results. Targeting
sequences in the cytoplasmic N-terminal of FasL likely direct
FasL trafficking to a CD63þ secretory compartment, as in
other cell types, FasL mutants lacking these sequences
relocalize to the cell surface [21].
The localization of FasL to intraluminal vesicles of cytolytic
granules is important as this will direct FasL to be released in its
more potent, membrane-bound form. Our results support
earlier findings that FasL is found on exosomes [30], as ILVs
will give rise to exosomes when released. In T cells, TCR
activation induces colocalization of ADAM10 and FasL and
cleavage of FasL into a soluble form [31], but it is not clear
whether this occurs in NK cells. Although a significant portion
of FasL-containing vesicles traffic to the immune synapse (IS)
during conjugate formation with target cells, in a majority of
cells, a portion of FasL localizes to the distal pole of the NK cell
away from the immune synapse. FasL at the immune synapse is
likely involved in the target cell killing, confirming functional
studies showing that FasL and perforin/granzyme mediated
target cell killing are independent cytotoxic effectors in CD8þ
cytotoxic T cells andNK cells [5, 32]. The FasL at the distal pole
of the cell may be in excess of the traffickingmachinery needed
to deliver FasL to the immune synapse, or may serve other
functions. In T cells, the distal pole of the cell sequesters
molecules such as CD43 away from the immune synapse and
regulates T cell activation [33]. The function of the distal pole
complex in NK cells is less well understood, but FasL localized
to the distal pole would be well-positioned to induce cell death
in bystander cells. In CD4þ T cells, FasL induced by
restimulation through the TCR can kill other T cells not
presenting antigen to the effector cells in an autocrine manner
through FasL secreted in microvesicles [34]. Since FasL-GFP is
expressed at supra-physiological levels in these cell lines, this
findingwill need tobe confirmedwith endogenousFasL aswell,
although the localization of FasL to the immune synapse inNK
cells is similar to what has been observed with native FasL in
CD8þ T cells [2]. As FasL trafficking is crucial for its function,
these data provide additional information that may be useful
for designing strategies to modulate the effects of FasL in
relevant disease states.
Materials and Methods
Cell lines and culture
The human natural killer-like (NK) cell line YT was cultured
in RPMI-1640 medium supplemented with 10% FCS,
100UmL1 rhIL-2 (Proleukin), 2mM L-glutamine, 50mM
b-mercaptoethanol, (100UmL1) penicillin/ (100mgmL1)
streptomycin, and 1% sodium pyruvate (Gibco, Thermo-
fisher Scientific,Waltham,MA,USA). TheEpstein-BarrVirus
(EBV) transformed human B cell line, 721.221 was main-
tained in RPMI-1640, supplemented with 10% FCS and
(100UmL1) penicillin/ (100mgmL1) streptomycin.
Lentiviral transduction of FasL-GFP in YT cells
YT cells were transduced with GFP-FasL using the lentiviral
vector, pHR-SINcPPT-SGW as previously described (Stinch-
combe et al., 2006). For each transduction experiment, 5 106
YT cells were spun, pelleted, and resuspended in 1mL of
lentiviral supernatant in the presence of 6mgmL1 of
polybrene (Sigma–Aldrich, Merck, Darmstadt, Germany)
and plated in 24-well plates. Cells were ‘‘spinfected’’ by
centrifugation at 2500 rpm for 30min at RT. Plates were then
incubated at 378C. About 24h post-infection viral supernatant
was carefully removed from the top of the wells of infected YT
cells and replaced with fresh complete YT medium. GFP-FasL
expression in YT cells was assayed by flow cytometry.
Transduced YT cell clones were isolated by limiting dilution
and selected based on GFP-expression using flow cytometry.
Confocal immunofluorescence microscopy
YT cells were resuspended at 106 cells mL1 in serum-free
RPMI-1640 and adhered to glass slides for 30min at 378C,
washed with PBS, containing 0.1% bovine serum albumin
(BSA) (Sigma–Aldrich), 0.02% sodium azide and fixed with
ice-cold methanol for 5min and washed in PBS before
incubating for 1 h at room temperature in blocking buffer
(PBS, 1% BSA). Samples were incubated with primary
antibodies in PBS, 0.2% BSA for 1 h at room temperature,
or overnight at 48C and washed extensively in PBS, 0.2% BSA
before adding secondary antibodies for 40min at room
temperature. Nuclei were stained with Hoechst 33342
(1:20,000) (Invitrogen, Thermofisher Scientific, Waltham,
MA, USA) in PBS for 1–2min before mounting with number
1.5 coverglass and mounting medium (Mowiol). Fixed images
were examined at room temperature using eitherZeiss LSM510
confocal microscope (Carl Zeiss, Inc., Oberkochen, Germany),
or with laser-scanning spinning-disk confocal system (Andor
Revolution) with lasers exciting at 405, 488, 543, and 633 nm
using the 63x or 100x (Plan-Apochromat, NA 1.40) oil
immersion objective. Images were acquired using Image Pro
(Zeiss, Inc.) or IQ software (Andor, Belfast, Northern Ireland).
Colocalization analysis
Imaris Scientific Image Processing and Analysis Software
(BitPlane Scientific Software, Zurich, Switzerland) was used
for colocalization analysis. Each image stack contained several
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cells, with 76 cells (12 stacks) analyzed for GFP-FasL to
perforin colocalization, 78 cells (14 stacks) for GFP-FasL to
LAMP1 colocalization, 31 cells (7 stacks) for GFP-FasL to
CD63 colocalization and 237 cells (35 stacks) for GFP-FasL to
anti-GFP antibody colocalization. GFP-FasL was displayed as
channel A. Anti-perforin, anti-LAMP1, anti-CD63 (Alexa-
Fluor 568-coupled secondary antibody) or anti-GFP (Alex
Fluor 533-coupled secondary antibody) staining was dis-
played as channel B. Channel thresholds were set as to include
the full range of data as displayed in the colocalization tool 2D
histogram. For quantitative colocalization analysis, each
image stack was analyzed by creating amask via the GFP-FasL
channel (threshold 600–750) that focuses the region of
interest (ROI) for colocalization analysis to the FasLþ
structures. Pearson’s coefficients for each mask (ROI) were
plotted using Prism software and statistical analysis was done
using the one-way ANOVA test (parametric, (F
(6,94)¼ 153.6, p< 0.0001)) plus Bonferroni’s Multiple
Comparison post hoc test (95% confidence intervals).
NK-target cell conjugate formation
Equal volumes of GFP-WT FasL-expressing YT clones and
721.221 B cells were resuspended at a concentration of 0.75–
.0.80 106 cellsmL1 in serum-free medium. Prior to this
final working concentration, all cells were washed in
complete RPMI-1640 medium. A total volume of 300mL
of target cells was plated on a 35mm petri dish (MatTek
Corporation) for 5min at 378C in RPMI-1640. A 1.5mL of
Imaging Buffer which was prepared in RPMI-1640 (no
phenol red), supplemented with 10% FCS, 25mM HEPES,
Penicillin/Streptomycin, and L-glutamine, was added to the
plated cells. YT cells were spun down in Imaging Buffer for
2min at RT, resuspended and then added on top of target
cells in the petri dish. Cells were fixed at the indicated times
and imaged by confocal miscroscopy as described above.
Electron microscopy
Cells were fixed with 4% PFA, 0.2% glutaraldehyde/ PBS. Cells
were washed with 15mM glycine and scraped and pelleted in
12% gelatin. Pellets were cut out and infiltrated with 2.3M
sucrose before being mounted onto pins. Ultrathin cryosections
were cut at 1208C using a Leica Ultracut UCT microtome.
Sections were picked up with 2.3M sucrose. Sections were
labeled with a rabbit polyclonal anti-GFP antibody (Abcam,
Cambridge, UK—ab6556) and 10nm Protein-A gold. Sections
were visualised with a FEI Tecnai TEM at 80kV.
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SUPPORTING INFORMATION
Additional supporting information may be found in the
online version of this article at the publisher’s web-site.
Figure S1. Validation of GFP as a marker for FasL
subcellular localization. Confocal immunofluorescence
microscopy of YT cells stably expressing wild-type FasL-
GFP fusion protein (green) additionally stained with
antibodies to either FasL (Nok1 antibody, red, A) or GFP
(anti-GFP antibody, red, B). The nuclei of YT cells were
labeled using Hoechst dye.
Figure S2. Line plot analysis of FasL colocalization with
secretory lysosome markers. Confocal immunofluorescence
microscopy (slices) of YT cells stably expressing wild-type
FasL (green) were stained with anti-LAMP1 antibody to
label LAMP 1þ compartments (B), anti-CD63 antibody to
label CD63þ compartments (C), and with anti-perforin
antibody (dG9) to label perforin-containing compartments
(A). The nuclei of YT cells were labeled with Hoechst dye.
Merge1 is GFP-FasL (green), Hoechst (blue), and the vesicle
of interest (LAMP1, CD63, perforin, red). Merge2 is GFP-
FasL (green), Hoechst (blue), and anti-GFP (White). The
lines in the graph (D) represent the presence of FasL (green)
and LAMP1, CD63 or perforin marker (red), and Hoechst
staining (blue), and anti-GFP (black) going across the line
shown in the FasL panel.
Figure S3. Colocalization of FasL and CD63 at the immune
synapse in living cells. YT cell clones that express GFP-FasL
(green) and were transfected with mCherry-CD63 to express
CD63 (in red). Target cells (blue) (721.221 B cell line) were
loaded with Coumarin-blue dye and then added to YT cells.
Each picture is a merge of blue, red and green confocal
immunofluorescence images. The individual pictures mak-
ing up the montage were taken from live cell time-lapse
video microscopy. Images were acquired‘ from 0 to 12min
after YT and B cells came into contact.
Supplemental Video 1, accompanying Figure 5A Supple-
mental Video 1, accompanying Figure 5A. YT cell clones that
express GFP-FasL (green) were transfected with LifeAct-
apple plasmid to track F-actin (red). Target cells (721.221 B
cell line) were added to YT cells. The video is a merge of red
and green confocal immunofluorescence images. This live
cell time-lapse video was taken from 0 to 12min after YT and
B cells came into contact. The video plays at 100 real-time
speed (40 frames acquired at 20 s intervals played at 5 frames
per second).
Supplemental Video 2, accompanying Figure S3 Supple-
mental Video 2, accompanying Figure S3. YT cell clones that
express GFP-FasL (green) and were transfected with
mCherry-CD63 to express CD63 (in red). Target cells
(blue) (721.221 B cell line) were loaded with Coumarin-blue
dye and then added to YT cells. The video is a merge of the
red, green and blue confocal immunofluorescence images.
This live cell time-lapse video was taken from 0 to 12min
after YT and B cells came into contact. The video plays at
100 real-time speed (40 frames acquired at 20 s intervals
played at 5 frames per second).
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